Show simple item record

dc.date.accessioned2021-04-22T20:27:05Z
dc.date.available2021-04-22T20:27:05Z
dc.date.issued2021-04-22
dc.identifier.govdocPAHO/HSS/MT/COVID-19/21-0006
dc.identifier.urihttps://iris.paho.org/handle/10665.2/53772
dc.description.abstractThis consultation document lists and provides definitions of adverse events of special interest and adverse events following immunization for COVID-19 vaccines that can be used as a common language for reporting these events. The importance of standardizing definitions of adverse events and their guidelines is that this will allow for data comparability and will lead to a better understanding of the adverse event. COVID-19 vaccine safety surveillance will be of the utmost importance and will require collaboration by all stakeholders once a vaccine is introduced. Sharing data and information will be critical and thus criteria and definitions for events and clinical developments need to be standardized as part of the vaccine safety surveillance. Regarding post-vaccination adverse event surveillance, conventional vaccine safety surveillance and pharmacovigilance systems will need to adapt quickly to new surveillance techniques and ensure that post-vaccination safety and exposure information is collected and processed quickly. Clinical studies of vaccines that have received emergency authorization for use will require close follow-up by multiple stakeholders to ensure that use of these vaccines will continue to be as safe and effective in the field as in clinical trials.en_US
dc.language.isoenen_US
dc.publisherPAHOen_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 IGO*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/igo/*
dc.subjectCOVID-19en_US
dc.subjectVaccinationen_US
dc.subjectCoronavirus Infectionsen_US
dc.subjectBetacoronavirusen_US
dc.subjectVaccinesen_US
dc.subjectImmunizationen_US
dc.subjectSurveillanceen_US
dc.subjectPharmacovigilanceen_US
dc.titleConsultation Document for Case Definitions: Adverse Events of Special Interest and Adverse Events Following Immunization during COVID-19 Vaccine Introductionen_US
dc.typeTechnical reportsen_US
dc.rights.holderPan American Health Organizationen_US
dc.contributor.corporatenamePan American Health Organizationen_US
paho.isfeatured0en_US
paho.publisher.countryUnited Statesen_US
paho.publisher.cityWashington, D.C.en_US
paho.source.centercodeUS1.1en_US
paho.relation.languageVersion10665.2/54832
paho.contributor.departmentHealth Systems and Services (HSS)en_US
paho.iswhotranslationNoen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 3.0 IGO
This notice should be preserved along with the article's original URL.Attribution-NonCommercial-ShareAlike 3.0 IGO